Abstract: A general methodology for the development of sensitive and selective sensors that can achieve a low cost detection of glucose without using enzymes is disclosed. The method uses carbon nanofiber (CNF) array electrodes for the electrochemical detection of glucose. CNFs grown by plasma enhanced chemical vapor deposition (PECVD) with diameters ranging from 13-160 nm and a height of approximately one micrometer are preferred. The CNFs have a sensitivity of 2.7 ?A/mM cm2 and detection limit of 2 mM. Also provided are methods of preparing the CNF sensors and kit components. Methods of using such CNF sensors for detecting target agents, particularly glucose, are also provided.

Abstract: A general methodology for the development of sensitive and selective sensors that can achieve a low cost detection of glucose without using enzymes is disclosed. The method uses carbon nanofiber (CNF) array electrodes for the electrochemical detection of glucose. CNFs grown by plasma enhanced chemical vapor deposition (PECVD) with diameters ranging from 13-160 nm and a height of approximately one micrometer are preferred. The CNFs have a sensitivity of 2.7 ?A/mM cm2 and detection limit of 2 mM. Also provided are methods of preparing the CNF sensors and kit components. Methods of using such CNF sensors for detecting target agents, particularly glucose, are also provided.

Abstract: Methods, apparatuses, and systems for creating an overlay application for use within a broadcast communications system are disclosed. A method in accordance with one or more embodiments of the present invention comprises collecting image data from a computer network, generating at least one selectable area within the image data, associating a function with the at least one selectable area, and selectively displaying the image data on a monitor simultaneously with a broadcast data stream, wherein selection of the at least one selectable area executes the associated function.

Abstract: Methods, apparatuses, and systems for creating an overlay application for use within a broadcast communications system are disclosed. A method in accordance with one or more embodiments of the present invention comprises collecting image data from a computer network, generating at least one selectable area within the image data, associating a function with the at least one selectable area, and selectively displaying the image data on a monitor simultaneously with a broadcast data stream, wherein selection of the at least one selectable area executes the associated function.

Abstract: The present disclosure describes a viscometer for measurements of both Newtonian and non-Newtonian fluids. In one embodiment, the viscometer comprises (i) a storage reservoir to store a test fluid, (ii) at least one drain tube assembly comprising a capillary drain tube, (iii) a collector for collecting said test fluid, and (iv) a detector. In addition, its novel viscosity equations suitable for the described viscometers are provided and illustrated for the application to Newtonian fluids and non-Newtonian fluids.

Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).

Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

Abstract: This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I).

Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).

Abstract: This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Abstract: This application relates to a compound of formula I (or a pro-drug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I).

Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Abstract: A heated massage ball apparatus has a ball that may be heated retained within a grip that allows for the ball to rotate freely therewithin. The ball may be heated, for example, in a microwave oven, and may be substantially hollow and filled with a liquid that retains heat. The grip is pliable enough to allow the forced insertion or ejection of the ball past its widest circumference. An opening in the bottom of the base may facilitate the removal of the ball from the base, whereby the user inserts a finger therein to force the ball out of the grip. A heating base can accept the grip and ball and provide heat to the ball, such as a heated conductor that extends through the bottom opening in the grip and heats the ball by direct contact and thermal conduction. An electrical circuit may be included that provides on/off and temperature controls, a heating element, a temperature-sensing means, a thermostat, and a display for indicating a target and current ball temperatures.

Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceuical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermedicates therefor.

Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.